# A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer

Source: https://onco.cc/trials/nct07299825/  
OnCo record `nct07299825` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of A166 in HER2-positive breast cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., now recruiting.

## Summary

A Study of A166 in Patients With HER2-Positive Unresectable or Metastatic Breast Cancer is a phase 2 interventional study registered as NCT07299825 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 40 participants planned, started 2024-09-20 and due to reach its primary completion in 2027-09-20. Interventions recorded: A166.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07299825
- Phase: 2
- Setting: Phase 2 Study of A166 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With TOP1-ADCs
- Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- Enrolled: 40

## Sources

- ClinicalTrials.gov NCT07299825: https://clinicaltrials.gov/study/NCT07299825

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/)
- drugs: [A166](https://onco.cc/drugs/a166/)
- companies: [Sichuan Kelun-Biotech](https://onco.cc/companies/kelun-biotech/)

---
JSON: https://onco.cc/api/v1/entities/nct07299825.json